Cargando…

PB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD): RESULTS OF A REAL-WORLD EVIDENCE STUDY

Detalles Bibliográficos
Autores principales:	Ionova, T., Vinogradova, O., Kochkareva, Y., Ado, E., Kaplanov, K., Shirokova, M., Shelekhova, T., Levanov, A., Kopylova, A., Li, O., Mitina, T., Rukavitsyn, O., Simashova, P., Anchukova, L., Babich, E., Dasheeva, D., Demchenkova, M., Dubov, S., Esenina, T., Ivanova, L., Kravchuk, T., Rimashevskaya, E., Saraeva, N., Savinova, M., Volkova, S., Porfirieva, N., Nikitina, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429208/ http://dx.doi.org/10.1097/01.HS9.0000850916.45282.84

Ejemplares similares

P1724: QUALITY OF LIFE AND UNMET NEEDS AMONG PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS: RESULTS OF THE NATIONWIDE SURVEY
por: Ionova, T., et al.
Publicado: (2022)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

P1692: UNMET NEEDS IN PATIENTS WITH “LOW RISK” POLYCYTHEMIA VERA (PV): SYMPTOM BURDEN AND QUALITY OF LIFE
por: Nikitina, Tatiana, et al.
Publicado: (2023)

Challenges, facilitators and barriers to the adoption and use of a web-based national IRD registry: lessons learned from the IRD-PT registry
por: Marques, João Pedro, et al.
Publicado: (2022)

Global Analysis of Gene Expression in the Developing Brain of Gtf2ird1 Knockout Mice
por: O'Leary, Jennifer, et al.
Publicado: (2011)

Gtf2ird1-Dependent Mohawk Expression Regulates Mechanosensing Properties of the Tendon
por: Kayama, Tomohiro, et al.
Publicado: (2016)

COVID-19 Vaccines in Inherited Retinal Degenerations (IRD), Fears, Ideas and Real Interactions
por: Vingolo, Enzo Maria
Publicado: (2022)

PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING
por: Ionova, T., et al.
Publicado: (2022)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
por: Park, Hyunkyung, et al.
Publicado: (2022)

SUMOylation of GTF2IRD1 Regulates Protein Partner Interactions and Ubiquitin-Mediated Degradation
por: Widagdo, Jocelyn, et al.
Publicado: (2012)

PB2703: ISA-KD IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL LIFE.
por: Llorente, Dunia De Miguel, et al.
Publicado: (2023)

A Role for Transcription Factor GTF2IRD2 in Executive Function in Williams-Beuren Syndrome
por: Porter, Melanie A., et al.
Publicado: (2012)

Deciphering the genetic architecture and ethnographic distribution of IRD in three ethnic populations by whole genome sequence analysis
por: Biswas, Pooja, et al.
Publicado: (2021)

Broadening INPP5E phenotypic spectrum: detection of rare variants in syndromic and non-syndromic IRD
por: Sangermano, Riccardo, et al.
Publicado: (2021)

Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes
por: Padariya, Monikaben, et al.
Publicado: (2021)

Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
por: Chari, Ajai, et al.
Publicado: (2019)

Genetic Screen in Drosophila Larvae Links ird1 Function to Toll Signaling in the Fat Body and Hemocyte Motility
por: Schmid, Martin R., et al.
Publicado: (2016)

Design, development and deployment of a web-based interoperable registry for inherited retinal dystrophies in Portugal: the IRD-PT
por: Marques, João Pedro, et al.
Publicado: (2020)

National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD
por: Hasseli, Rebecca, et al.
Publicado: (2020)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

A meta-analysis of single-subject reading intervention studies for struggling readers: using Improvement Rate Difference (IRD)
por: Kim, Dongil, et al.
Publicado: (2020)

A Systematic Review and Meta-Analyses of Interventional Clinical Trial Studies for Gene Therapies for the Inherited Retinal Degenerations (IRDs)
por: Tuohy, Gearóid P., et al.
Publicado: (2021)

PB2252: TREATMENT OF ANEMIA IN PATIENTS WITH GASTROINTESTINAL AND CHRONIC LIVER DISORDERS BASED ON PREDOMINANT PATHOGENETIC FACTOR.
por: Rybina, O., et al.
Publicado: (2022)

P1207: MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R-DA-EPOCH-21 AND R-MNHL-BFM-90 ± AUTO- HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B-CELL LAR
por: Magomedova, A., et al.
Publicado: (2022)

Association of GTF2IRD1–GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients
por: Xie, Jing-Lu, et al.
Publicado: (2019)

GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8(+) T cells infiltration in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

A hidden structural variation in a known IRD gene: a cautionary tale of two new disease candidate genes
por: Scott, Hilary A., et al.
Publicado: (2022)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01
por: Bobin, A., et al.
Publicado: (2022)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee
por: Han, Jinu, et al.
Publicado: (2023)

Development of a novel prediction model based on protein structure for identifying RPE65-associated inherited retinal disease (IRDs) of missense variants
por: Wu, Jiawen, et al.
Publicado: (2023)

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
por: Gengenbach, Laura, et al.
Publicado: (2021)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
por: Du, Juan, et al.
Publicado: (2023)

RNA-Seq analysis of Gtf2ird1 knockout epidermal tissue provides potential insights into molecular mechanisms underpinning Williams-Beuren syndrome
por: Corley, Susan M., et al.
Publicado: (2016)

GTF2IRD1 on chromosome 7 is a novel oncogene regulating the tumor‐suppressor gene TGFβR2 in colorectal cancer
por: Nambara, Sho, et al.
Publicado: (2019)

1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
por: Zakurdaeva, K., et al.
Publicado: (2021)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
por: Offner, Fritz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d51a29ctcl1abbn316tdmj88jk